Results 231 to 240 of about 631,638 (309)
Evaluation of Stereopsis Performance, Gaze Direction and Pupil Diameter in Post-COVID Syndrome Using Machine Learning. [PDF]
BiomedicinesKnauer TS, Mardin CY, Rech J, Michelson G, Stog A, Zott J, Steußloff F, Güttes M, Sarmiento H, Ilgner M, Jakobi M, Hohberger B, Schottenhamml J. +12 moreeuropepmc +1 more sourcePsilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial
Addiction, EarlyView.Abstract Background and Aims
Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent +7 morewiley +1 more sourceCorrection: All eyes on PCS: analysis of the retinal microvasculature in patients with post-COVID syndrome-study protocol of a 1 year prospective case-control study. [PDF]
Eur Arch Psychiatry Clin NeurosciKuchler T, Hausinger R, Braunisch MC, Günthner R, Wicklein R, Knier B, Bleidißel N, Maier M, Ribero A, Lech M, Adorjan K, Stubbe H, Kotliar K, Heemann U, Schmaderer C. +14 moreeuropepmc +1 more sourceRole for Complement C5 in Eosinophilic Inflammation of Severe Asthma
Allergy, EarlyView.Complement activation module, particularly C5, is positively associated with eosinophilic inflammation in severe asthma cohorts. Elevated C5 expression correlates with poor lung function improvement and persistent eosinophilic inflammation. Mouse model studies confirm that C5 exacerbates eosinophilic inflammation, highlighting its potential as a ...Cong Dong, Shaohua Lu, Zhenan Deng, Xuliang Cai, Huahao Shen, Guochao Shi, Changxing Ou, Zuofu Peng, Wei Jiang, Xiuhua Fu, Changzheng Wang, Meiling Jin, Zhongmin Qiu, Xiaoyang Wei, Wei Gu, Kewu Huang, Qiang Li, Xiangyan Zhang, Nanshan Zhong, Kian Fan Chung, Qingling Zhang, on behalf of C‐BIOPRED Consortium, Jiangtao Lin, Yongming Zhang, Nan Su, Xiaoyan Zhang, Qing Zhao, Ying Nong, Ping Chen, Tianyi Zhu, Binbin Ji, Yan Wang, Haitao Zhao, Jinbao Wang, Zhiyuan Zhang, Xiaona Yang, Chunhua Wei, Jing Han, Nong Yu, Qiang Li, Zhifu Yang, Yanhong Liu, Guohua Li, Huadong Guan, Shuping Zhang, Xiuhua Fu, Lihong Wang, Lingxin Meng, Zhenting Sun, Guangqin Cao, Lei Zhao, Kewu Huang, Hong Zhang, Wen Wang, Li An, Yangyu Chen, Yanli Gao, Xiaoxia Liu, Huifen Zhai, Fang Lin, Zhaohui Zhong, Zhongguang Wen, Yan Xiao, Jian Kang, Linfei Kong, Xinming Su, Xue Yan, Dijia Zhou, Huaping Tang, Wei Han, Yi Shu, Tintian Li, Lixin Xie, Hong Hu, Bo Liu, Yuzhu Li, Longmei Fan, Yue Zhang, Shifeng Zhao, Xiaofang Liu, Yuhong Wang, Xichun Zhang, Xinmao Wang, Pen Bai, Guangfa Wang, Yan Hu, Zhanwei Hu, Ju Cao, Bei He, Rui Wu, Xiaoyan Gai, Hong Zhu, Zhihai Han, Jiyi Meng, Wei Chen, Li Ma, Zhenqian Liu, Chunyang Zhang, Yan Zhang, Huahao Shen, Fugui Yan, Bin Shen, Xinghong Wang, Hao Zhang, Yinghua Yin, Jinkai Liu, Yanxiong Mao, Mao Huang, Xin Yao, Mao Huang, Ji Zhou, Zhenzhen Wu, Ping Yan, Yujie Zhang, Xinling Yang, Ningfei Ji, Fan Fei, Wanzhen Fu, Yi Yang, Yuting Shi, Wangjian Cha, Guochao Shi, Min Zhou, Wei Tang, Wei Chen, Jun Zhou, Wenjie Yang, Lei Zhu, Meiling Jin, Liping Xue, Li Li, Chun Li, Yin Gong, Qiang Li, Guogang Xie, Luhong Bao, Wuping Bao, Nianyun Li, Fengming Ding, Min Zhang, Zhongmin Qiu, Li Yu, Jungang Xie, Lingling Yi, Xianghuai Xu, Qiang Chen, Junjun Tang, Jinfu Xu, Xiaobing Ji, Jingyun Shi, Bo Su, Xiaojun Yang, Jiuwen Bai, Shuo Liang, Kebing Cheng, Wei Gu, Jiyong Ma, Yun Liu, Jun Ren, Shan Mao, Qingling Zhang, Baoqing Sun, Jiaxing Xie, Rihuang Qiu, Zhiqiang Wang, Peiyan Zhen, Wenting Luo, Changgao Zhong, Wei Luo, Yanqing Xie, Xinxin Yu, Wenting Yu, Wei He, Changzheng Wang, Qianli Ma, Min Wan, Mingzhou Zhang, Haining Li, Shaoxi Cai, Haijin Zhao, Yanmei Ye, Fang Zhou, Laiyu Liu, Guohua Huang, Jianpeng Liang, Jianping Zhao, Jungang Xie, Qiongjie Hu, Kaiyan Li, Wang Ni, Guohua Zheng, Weining Xiong, Lingling Yi, Xihu Du, Yunhui Zhang, Zhi Li, Xiaoqiong Tan, Feng Liao, Shenglan Wang, Yijiang Huang, Xinjun Cai, Kai Liu, Shaojing Sheng, Yihui Fu, Shenghua Sun, Qiang Zhang, Jinweng Cai, Ye Ling, Pin Chen, Hong Luo, Lv Liu, Zhijun Liu, Yuling Tang, Yusheng Yan, Guiyan Mo, Long Wen, Yinqun Zhu, Du Fan +217 morewiley +1 more sourceLong‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria
Allergy, EarlyView.Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...Ana M. Gimenez‐Arnau, Marcus Maurer, Adam Reich, Chia‐Yu Chu, Diana Deleanu, Gordon Sussman, Jorge Sanchez, Knut Brockow, Koremasa Hayama, Michihiro Hide, Mohamed Denguezli, Raisa Meshkova, Roberta F. J. Criado, Sarbjit Saini, Solange Valle, Eva Hua, Pengpeng Wang, Alis Burciu, Isabelle Indermuehle, Vineeth Varanasi, Yolandi Joubert, Thomas Severin, Manmath Patekar +22 morewiley +1 more sourceLarge-Scale Psychometric Assessment and Validation of the Modified COVID-19 Yorkshire Rehabilitation Scale Patient-Reported Outcome Measure for Long COVID or Post-COVID Syndrome. [PDF]
J Med VirolHorton M, Smith AB, Milne R, Winch D, Rayner C, Halpin S, O'Connor R, Rocha Lawrence R, Greenwood DC, Bakerly ND, Evans R, Kwon J, Dawes H, Wood C, Williams P, Master H, Mansoubi M, De Kock JH, Mullard J, Ormerod M, Mir G, Petrou S, O'Connor DB, Sivan M, LOCOMOTION Consortium. +24 moreeuropepmc +1 more sourceUpdate on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper
Allergy, EarlyView.ABSTRACT
In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato +20 morewiley +1 more source
